Text Size

Dextroamphetamine-Amphetamine Compared With Methylphenidate in Treating Children Who Have Problems With Memory, Attention, Thinking, and Depression Caused By Cancer Treatment

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00069927
First received: October 3, 2003
Last updated: September 11, 2010
Last verified: July 2006
History of Changes
  Purpose

RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer, and may help decrease depression.

PURPOSE: This randomized phase II trial is studying dextroamphetamine-amphetamine to see how well it works compared to methylphenidate in treating depression and problems with memory, attention, and thinking in children who have undergone CNS treatment for cancer. This trial will also study how often depression is seen and if these medications might help.


Condition Intervention Phase
Depression
Neurotoxicity
Unspecified Childhood Solid Tumor, Protocol Specific
 Drug: dextroamphetamine-amphetamine
Drug: methylphenidate hydrochloride
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Supportive Care
Official Title: Adderall-XR Versus Concerta For Cancer Treatment-Related Neurocognitive Sequelae And Depression In Pediatric Patients: A Randomized Phase II Study

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Response rate as measured by Wechsler Intelligence Scale for Children-III (WISC III) subtest: Coding, Symbol Search and Digit Span at baseline, and 3 weeks after the start of study treatment

Secondary Outcome Measures:
  • Durability of response as measured by WISC III subtest: Coding, Symbol Search and Digit Span at 12 weeks after the start of study treatment
  • Depression as measured by Children's Depression Inventory Short Version (CDI-S) at baseline, weeks 3 and 12

Estimated Enrollment: 177
Study Start Date: August 2003
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Compare the response rates in pediatric cancer patients with treatment-related neurocognitive sequelae treated with dextroamphetamine-amphetamine vs methylphenidate.
  • Compare the durability of response at 12 weeks in patients who show a response at 3 weeks after treatment with these drugs.
  • Determine whether patients who have no response to one of these study drugs can respond to the other study drug.
  • Determine the prevalence of depression and possible response to neurostimulant therapy in this patient population.

OUTLINE: This is a randomized, multicenter study.

Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral dextroamphetamine-amphetamine once daily for 3 weeks. Patients who achieve response (based on neurocognitive testing) continue treatment for a total of 12 weeks. Patients with no response after 3 weeks cross over to arm II after a 48-hour washout period.
  • Arm II: Patients receive oral methylphenidate once daily for 3 weeks. Responding patients continue treatment for a total of 12 weeks. Patients with no response after 3 weeks cross over to arm I after a 48-hour washout period.

Depression and neurocognitive function are assessed at baseline, 3 weeks, and end of study.

PROJECTED ACCRUAL: A total of 177 patients (approximately 88 per treatment arm) will be accrued for this study within 3 years.

  Eligibility

Ages Eligible for Study:   6 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of a malignancy and received prior CNS treatment (e.g., surgery and/or radiotherapy and/or intrathecal chemotherapy)

    • Patients treated with prior systemic chemotherapy alone are not eligible
    • At least 6 months since prior treatment
  • Cancer-free for at least 6 months
  • Neurocognitive function at least 1 standard deviation below the level of performance predicted by patient's IQ on at least 2 of 3 WISC®-III subtests*
  • No diagnosis of attention deficit disorder or attention-deficit hyperactivity disorder before cancer diagnosis NOTE: *Patients who are not eligible for randomization based on test results may be retested every 3 months

PATIENT CHARACTERISTICS:

Age

  • 6 to 17

Performance status

  • Not specified

Life expectancy

  • Not specified

Hematopoietic

  • Not specified

Hepatic

  • Not specified

Renal

  • Not specified

Cardiovascular

  • No history of cardiovascular disease or uncontrolled hypertension

Other

  • No history of hyperthyroidism
  • Estimated IQ of at least 65 (based on the WRAT-3™ reading subtest)
  • Not blind
  • No glaucoma
  • No family history of motor and phonic tics or Tourette's syndrome

  • No seizures not controlled by antiepileptic drugs

    • Patients not currently experiencing seizures and who have been on a stable dose of antiepileptic drugs for at least 12 weeks are eligible
  • Proficient in English
  • Not pregnant or nursing
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • See Disease Characteristics

Endocrine therapy

  • Not specified

Radiotherapy

  • See Disease Characteristics

Surgery

  • See Disease Characteristics

Other

  • No concurrent antidepressants, antipsychotics, or other stimulants
  • No concurrent monoamine oxidase inhibitors
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00069927

Locations
United States, Florida
University of Florida Shands Cancer Center
Gainesville, Florida, United States, 32610-0296
Sacred Heart Children's Hospital
Pensacola, Florida, United States, 32504
CCOP - Florida Pediatric
Tampa, Florida, United States, 33682-7757
St. Joseph's Children's Hospital of Tampa
Tampa, Florida, United States, 33677-4227
United States, Georgia
MBCCOP-Medical College of Georgia Cancer Center
Augusta, Georgia, United States, 30912-4000
United States, Michigan
William Beaumont Hospital - Royal Oak Campus
Royal Oak, Michigan, United States, 48073
United States, Texas
Wilford Hall Medical Center
Lackland Air Force Base, Texas, United States, 78236-5300
CHRISTUS Santa Rosa Children's Hospital
San Antonio, Texas, United States, 78207
MBCCOP - South Texas Pediatrics
San Antonio, Texas, United States, 78229-3900
Sponsors and Collaborators
University of South Florida
National Cancer Institute (NCI)
Investigators
Study Chair: Margaret Booth-Jones, PhD University of South Florida
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT00069927     History of Changes
Other Study ID Numbers: CDR0000301614, MCC-0201, NCI-5899
Study First Received: October 3, 2003
Last Updated: September 11, 2010
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
unspecified childhood solid tumor, protocol specific
depression
neurotoxicity

Additional relevant MeSH terms:
Depression
Depressive Disorder
Neurotoxicity Syndromes
Behavioral Symptoms
Mood Disorders
Mental Disorders
Nervous System Diseases
Poisoning
Substance-Related Disorders
Amphetamine
Methamphetamine
Dextroamphetamine
Methylphenidate
Adderall
Central Nervous System Stimulants
 Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Dopamine Uptake Inhibitors

ClinicalTrials.gov processed this record on May 16, 2013